市場調查報告書

全身性紅斑性狼瘡(SLE)- 市場洞察,流行病學,市場預測 2028年

Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology, and Market Forecast - 2028

出版商 DelveInsight Business Research LLP 商品編碼 611054
出版日期 內容資訊 英文 234 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全身性紅斑性狼瘡(SLE)- 市場洞察,流行病學,市場預測 2028年 Systemic Lupus Erythematosus (SLE) - Market Insights, Epidemiology, and Market Forecast - 2028
出版日期: 2019年11月01日內容資訊: 英文 234 Pages
簡介

主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的全身性紅斑性狼瘡(SLE)的2017年的罹患數為48萬4,213人,同年的市場規模估算為約14億4,735萬美元。

本報告提供主要7個國家(美國、英國、德國、法國、義大利、西班牙、日本)的全身性紅斑性狼瘡(SLE)市場調查,疾病概要和現行的治療方法,已上市治療藥及新藥的簡介,整體及各國的市場趨勢,流行病學的預測,市場規模,性別、各重症度的患病數的變化與預測,未滿足需求,市場成長要素及障礙等資訊總括性彙整。

目錄

第1章 重要洞察

第2章 全身性紅斑性狼瘡(SLE):市場概要

  • 市場佔有率(成果值)
  • 市場佔有率(預測值)

第3章 疾病背景和概要:全身性紅斑性狼瘡(SLE)

  • 簡介
  • 危險因素
  • 原因
  • 症狀
  • 臨床症狀
  • 醫院
  • 治療及診斷所使用的生物製藥及生物標記
  • 診斷
  • 分類

第4章 流行病學和患者人口

  • 主要調查結果
  • 人口與預測參數
  • 主要7個國家的診斷患病數
  • 美國
    • 假設和根據
    • 整體診斷數
    • 整體診斷數:性別
    • 整體診斷數:各重症度
  • 歐盟5國
    • 德國
      • 整體診斷數
      • 整體診斷數:性別
      • 整體診斷數:各重症度
    • 法國
    • 義大利
    • 西班牙
    • 英國
  • 日本

第5章 現行治療

  • 歐洲風濕學會(EULAR)的推薦事項

第6章 未滿足需求

第7章 已上市治療藥

  • Benlysta:GlaxoSmithKline
    • 醫藥品概要
    • 法規的里程碑
    • 其他開發趨勢
    • 臨床開發
    • 安全性和有效性
    • 產品簡介

第8章 新藥

  • Key Cross Competition
    • 第三階段臨床實驗藥
    • 第二階段臨床實驗藥
    • 其他
  • Anifrolumab:AstraZeneca
    • 醫藥品概要
    • 其他開發趨勢
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Lupuzor: Immupharma
  • Baricitinib:Eli Lilly
  • Stelara(ustekinumab):Janssen Pharmaceutical
  • Atacicept:Merck KGaA
  • ILT-101:Iltoo Pharma
  • BIIB059:Biogen
  • CC-220:Celgene
  • Dapirolizumab pegol:UCB Pharma/ Biogen
  • IFNα Kinoid:Neovacs
  • ACT-334441(Cenerimod):Idorsia Pharmaceuticals
  • KZR-616: Kezar Life Sciences
  • Lulizumab(BMS-931699):Bristol-Myers Squibb
  • Obexelimab (XmAb5871): Xencor

第9章 潛力新藥候補

  • RSLV-132:Resolve Therapeutics
    • 醫藥品概要
    • 其他開發趨勢
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • VIB7734:VIELABIO
  • Tofacitinib:Pfizer

第10章 市場規模

  • 主要調查結果
  • 主要7個國家的市場規模:各現行治療藥物
  • 主要7個國家的市場規模:各新藥

第11章 美國的全身性紅斑性狼瘡(SLE)市場預測

  • 整體市場規模
  • 市場規模:各現行治療藥物
  • 市場規模:各新藥

第12章 歐洲5個國家的全身性紅斑性狼瘡(SLE)市場預測

  • 德國
    • 整體市場規模
    • 市場規模:各現行治療藥物
    • 市場規模:各新藥
  • 法國
  • 義大利
  • 西班牙
  • 英國

第13章 日本的全身性紅斑性狼瘡(SLE)市場預測

  • 整體市場規模
  • 市場規模:各現行治療藥物
  • 市場規模:各新藥

第14章 市場成長要素

第15章 市場障礙

第16章 關鍵意見領袖的意見

第17章 附錄

  • 報告方法

第18章 DelveInsight的服務內容

第19章 免責聲明

第20章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIMI0222

DelveInsight's 'Systemic Lupus Erythematosus (SLE)-Market Insights, Epidemiology, and Market Forecast-2028' report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Systemic Lupus Erythematosus in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, the current and forecasted market size of Systemic Lupus Erythematosus from 2017 to 2028 segmented by seven major markets.

The phenomenon of Systemic Lupus Erythematosus (SLE) is a prototypic autoimmune disease characterized by the production of antibodies to components of the cell nucleus in association with a diverse array of clinical manifestations. The primary pathological findings in patients with SLE are those of inflammation, vasculitis, immune complex deposition, and vasculopathy

According to the American College of Rheumatology "Systemic lupus erythematosus, is referred to as chronic (long-term) disease that causes systemic inflammation which affects multiple organs. In addition to affecting the skin and joints, it can affect other organs in the body such as the kidneys, the tissue lining the lungs (pleura), heart (pericardium), and brain."

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2028

Systemic Lupus Erythematosus - Disease Understanding and Treatment Algorithm

SLE is a disease of unknown etiology with a variety of presenting features and manifestations. The majority of the pathology in SLE is related to deposits of immune complexes in various organs, which triggers complement other mediators of inflammation. Symptoms vary from person to person, depending on what part of the body is affected, can be mild, moderate, or severe. Clinical manifestations are heterogeneous, vary as a result of the type of the disease and organ involvement of an individual. Diagnosis can be difficult because lupus mimics many other diseases; it requires clinical and serologic criteria.

Systemic Lupus Erythematosus Epidemiology

The Systemic Lupus Erythematosus epidemiology division provides insights about historical and current patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders (KOL).

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (Total Diagnosed Prevalent cases, Gender-Specific Prevalence, and Severity Specific Prevalence) scenario of Systemic Lupus Erythematosus in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2028.

According to DelveInsight, the total Diagnosed Prevalent cases of Systemic Lupus Erythematosus (SLE) in the 7MM was found to be 484,213 in 2017. The prevalence of Systemic Lupus Erythematosus in the 7MM is expected to increase during the study period of 2017-2028.

Systemic Lupus Erythematosus Drug Chapters

This segment of the Systemic Lupus Erythematosus report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

At present, the therapeutic market size of SLE in the US is mainly accounted for the management options consisting of Corticosteroids, Immunosuppressants, Antimalarials (Plaquenil) and Biologics (Rituximab, Belimumab). Nonsteroidal anti-inflammatory drugs (NSAIDs) may also be used to treat inflammation and pain.

Hydroxychloroquine (Plaquenil) and Belimumab (Benlysta) are approved therapies for the treatment of SLE in the US.

Detailed chapters of current therapies, such as Belimumab (GlaxoSmithKline) and emerging therapies, such as Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), Ustekinumab (Janssen Pharmaceutical), Atacicept (Merck), Dapirolizumab pegol (UCB Pharma/ Biogen), CC-220 (Celgene), IFNα KINOID (Neovacs), ILT-101 (Iltoo Pharma), BIIB059 (Biogen), Lulizumab (Bristol-MyersSquibb), Obexelimab (Xencor), KZR-616 (Kezar Life Sciences), Cenerimod (Idorsia Pharmaceuticals) and others have also been provided in the report.

Systemic Lupus Erythematosus Market Outlook

The Systemic Lupus Erythematosus market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology.

According to DelveInsight, the market for Systemic Lupus Erythematosus in 7MM was found to be approximately USD 1,447.35 million in 2017.

Systemic Lupus Erythematosus market size in the United States accounted for 71% of the total market in 2017. The US led the market in 2017, followed by the EU5 and Japan, respectively. Due to the high prevalence of this disease in the region, the Systemic Lupus Erythematosus treatment market in the US is expected to dominate the market during the forecast period (2019-2028).

Systemic Lupus Erythematosus Drugs Uptake

This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017 to 2028. The analysis covers market uptake by drugs; patient uptake by therapies, and sales of each drug.

The dynamics of Systemic Lupus Erythematosus market is anticipated to change in the coming years owing to the expected launch of emerging therapies, such as, Belimumab (GlaxoSmithKline) and emerging therapies, such as Anifrolumab (AstraZeneca), Lupuzor (ImmuPharma), Baricitinib (Eli Lilly), Ustekinumab (Janssen Pharmaceutical), Atacicept (Merck), Dapirolizumab pegol (UCB Pharma/ Biogen), CC-220 (Celgene), IFNα KINOID (Neovacs), ILT-101 (Iltoo Pharma), BIIB059 (Biogen), Lulizumab (Bristol-MyersSquibb), Obexelimab (Xencor), KZR-616 (Kezar Life Sciences), Cenerimod (Idorsia Pharmaceuticals)), and others in the Systemic Lupus Erythematosus market by 2028.

Systemic Lupus Erythematosus Report Insights

  • Patient Population of Systemic Lupus Erythematosus
  • Therapeutic Approaches
  • Pipeline Analysis
  • Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Systemic Lupus Erythematosus Report Key Strengths

  • 10-Year Forecast
  • 7MM Coverage
  • Epidemiology Segmentation
  • Drugs Uptake
  • Highly Analyzed Market
  • Key Cross Competition

Systemic Lupus Erythematosus Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Detailed Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Benefits

  • This DelveInsight report will help to develop Business Strategies by understanding the trends shaping and driving Systemic Lupus Erythematosus market
  • Organize sales and marketing efforts by identifying the best opportunities for Systemic Lupus Erythematosus market
  • To understand the future market competition in the Systemic Lupus Erythematosus market

Table of Contents

1. Key Insights

2. Systemic Lupus Erythematosus (SLE): Market Overview at a Glance

  • 2.1. Total Market Share (%) Distribution of SLE in 2017
  • 2.2. Total Market Share (%) Distribution of SLE in 2028

3. Disease Background and Overview: Systemic Lupus Erythematosus (SLE)

  • 3.1. Introduction
  • 3.2. Risk Factors
  • 3.3. Causes
  • 3.4. Symptoms
  • 3.5. Clinical Manifestation
  • 3.6. Pathogenesis
  • 3.7. Biologics and Biomarkers in the Treatment and Diagnosis of SLE
  • 3.8. Diagnosis
    • 3.8.1. Recent classification of SLE

4. Epidemiology and Patient Population

  • 4.1. Key Findings
  • 4.2. Population and Forecast Parameters
  • 4.3. Total Diagnosed Prevalent cases of SLE in 7MM
  • 4.4. United States
    • 4.4.1. Assumptions and Rationale
    • 4.4.2. Total Diagnosed Prevalent cases of SLE in the US
    • 4.4.3. Gender Specific cases of SLE in the US
    • 4.4.4. Severity Specific cases of SLE in the US
  • 4.5. EU5
  • 4.6. Germany
    • 4.6.1. Assumptions and Rationale
    • 4.6.2. Total Diagnosed Prevalent cases of SLE in Germany
    • 4.6.3. Gender Specific cases of SLE in Germany
    • 4.6.4. Severity Specific cases of SLE in Germany
  • 4.7. France
    • 4.7.1. Assumptions and Rationale
    • 4.7.2. Total Diagnosed Prevalent cases of SLE in France
    • 4.7.3. Gender Specific cases of SLE in France
    • 4.7.4. Severity Specific cases of SLE in France
  • 4.8. Italy
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Total Diagnosed Prevalent cases of SLE in Italy
    • 4.8.3. Gender Specific cases of SLE in Italy
    • 4.8.4. Severity Specific cases of SLE in Italy
  • 4.9. Spain
    • 4.9.1. Assumptions and Rationale
    • 4.9.2. Total Diagnosed Prevalent cases of SLE in Spain
    • 4.9.3. Gender Specific cases of SLE in Spain
    • 4.9.4. Severity Specific cases of SLE in Spain
  • 4.10. United Kingdom
    • 4.10.1. Assumptions and Rationale
    • 4.10.2. Total Diagnosed Prevalent cases of SLE in the UK
    • 4.10.3. Gender Specific cases of SLE in the UK
    • 4.10.4. Severity Specific cases of SLE in the UK
  • 4.11. Japan
    • 4.11.1. Assumptions and Rationale
    • 4.11.2. Total Diagnosed Prevalent cases of SLE in Japan
    • 4.11.3. Gender Specific cases of SLE in Japan
    • 4.11.4. Severity Specific cases of SLE in Japan

5. Current Treatment

  • 5.1. EULAR Recommendations

6. Unmet Needs

7. Marketed drugs

  • 7.1. Benlysta: GlaxoSmithKline
    • 7.1.1. Drug Description
    • 7.1.2. Regulatory Milestones
    • 7.1.3. Other Developmental Activities
    • 7.1.4. Clinical Development
    • 7.1.5. Safety and Efficacy
    • 7.1.6. Product Profile

8. Emerging Drugs

  • 8.1. Key Cross Competition
    • 8.1.1. Key Cross Competition: Phase III Emerging Therapies
    • 8.1.2. Key Cross Competition: Phase II Emerging Therapies
    • 8.1.3. Key Cross Competition: Other Emerging Potential Therapies
  • 8.2. Anifrolumab: AstraZeneca
    • 8.2.1. Drug Description
    • 8.2.2. Other Developmental Activities
    • 8.2.3. Clinical Development
    • 8.2.4. Safety and Efficacy
    • 8.2.5. Product Profile
  • 8.3. Lupuzor: Immupharma
    • 8.3.1. Drug Description
    • 8.3.2. Other Developmental Activities
    • 8.3.3. Clinical Development
    • 8.3.4. Safety and Efficacy
    • 8.3.5. Product Profile
  • 8.4. Baricitinib: Eli Lilly
    • 8.4.1. Drug Description
    • 8.4.2. Other Developmental Activities
    • 8.4.3. Clinical Development
    • 8.4.4. Safety and Efficacy
    • 8.4.5. Product Profile
  • 8.5. Stelara (ustekinumab): Janssen Pharmaceutical
    • 8.5.1. Drug Description
    • 8.5.2. Other Developmental Activities
    • 8.5.3. Clinical Development
    • 8.5.4. Safety and Efficacy
    • 8.5.5. Product Profile
  • 8.6. Atacicept: Merck KGaA
    • 8.6.1. Drug Description
    • 8.6.2. Other Developmental Activities
    • 8.6.3. Clinical Development
    • 8.6.4. Safety and Efficacy
    • 8.6.5. Product Profile
  • 8.7. ILT-101: Iltoo Pharma
    • 8.7.1. Drug Description
    • 8.7.2. Other Developmental Activities
    • 8.7.3. Clinical Development
    • 8.7.4. Safety and Efficacy
    • 8.7.5. Product Profile
  • 8.8. BIIB059: Biogen
    • 8.8.1. Drug Description
    • 8.8.2. Other Developmental Activities
    • 8.8.3. Clinical Development
    • 8.8.4. Safety and Efficacy
    • 8.8.5. Product Profile
  • 8.9. CC-220: Celgene
    • 8.9.1. Drug Description
    • 8.9.2. Clinical Development
    • 8.9.3. Safety and Efficacy
    • 8.9.4. Product Profile
  • 8.10. Dapirolizumab pegol: UCB Pharma/ Biogen
    • 8.10.1. Drug Description
    • 8.10.2. Other Developmental Activities
    • 8.10.3. Clinical Development
    • 8.10.4. Safety and Efficacy
    • 8.10.5. Product Profile
  • 8.11. IFNα Kinoid: Neovacs
    • 8.11.1. Drug Description
    • 8.11.2. Other Developmental Activities
    • 8.11.3. Clinical Development
    • 8.11.4. Safety and Efficacy
    • 8.11.5. Product Profile
  • 8.12. ACT-334441 (Cenerimod): Idorsia Pharmaceuticals
    • 8.12.1. Drug Description
    • 8.12.2. Other Developmental Activities
    • 8.12.3. Clinical Development
    • 8.12.4. Safety and Efficacy
    • 8.12.5. Product Profile
  • 8.13. KZR-616: Kezar Life Sciences
    • 8.13.1. Drug Description
    • 8.13.2. Clinical Development
    • 8.13.3. Safety and Efficacy
    • 8.13.4. Product Profile
  • 8.14. Lulizumab (BMS-931699): Bristol-Myers Squibb
    • 8.14.1. Drug Description
    • 8.14.2. Clinical Development
    • 8.14.3. Safety and Efficacy
    • 8.14.4. Product Profile
  • 8.15. Obexelimab (XmAb5871): Xencor
    • 8.15.1. Drug Description
    • 8.15.2. Other Developmental Activities
    • 8.15.3. Clinical Development
    • 8.15.4. Safety and Efficacy
    • 8.15.5. Product Profile

9. Other potential therapies

  • 9.1. RSLV-132: Resolve Therapeutics
    • 9.1.1. Drug Description
    • 9.1.2. Other Developmental Activities
    • 9.1.3. Clinical Development
    • 9.1.4. Safety and Efficacy
    • 9.1.5. Product Profile
  • 9.2. VIB7734: VIELABIO
    • 9.2.1. Drug Description
    • 9.2.2. Other Developmental Activities
    • 9.2.3. Clinical Development
    • 9.2.4. Product Profile
  • 9.3. Tofacitinib: Pfizer
    • 9.3.1. Drug Description
    • 9.3.2. Other Developmental Activities
    • 9.3.3. Clinical Development
    • 9.3.4. Safety and Efficacy
    • 9.3.5. Product Profile

10. Market Size

  • 10.1. Key Findings
  • 10.2. Total Market Size of SLE in 7MM
  • 10.3. Total Market Size of SLE by Therapies in 7MM

11. US: Market Outlook

  • 11.1. Total Market size of SLE in the US
  • 11.2. Market size of SLE by Current Therapies
  • 11.3. Market size of SLE by Emerging Therapies

12. EU-5: Market outlook

  • 12.1. Germany
    • 12.1.1. Total Market size of SLE in Germany
    • 12.1.2. Market size of SLE by Current Therapies
    • 12.1.3. Market size of SLE by Emerging Therapies
  • 12.2. France
    • 12.2.1. Total Market size of SLE in France
    • 12.2.2. Market size of SLE by Current Therapies
    • 12.2.3. Market size of SLE by Emerging Therapies
  • 12.3. Italy
    • 12.3.1. Total Market size of SLE in Italy
    • 12.3.2. Market size of SLE by Current Therapies
    • 12.3.3. Market size of SLE by Emerging Therapies
  • 12.4. Spain
    • 12.4.1. Total Market size of SLE in Spain
    • 12.4.2. Market size of SLE by Current Therapies
    • 12.4.3. Market size of SLE by Emerging Therapies
  • 12.5. United Kingdom
    • 12.5.1. Total Market size SLE in the UK
    • 12.5.2. Market size of SLE by Current Therapies
    • 12.5.3. Market size of SLE by Emerging Therapies

13. Japan: Market Outlook

  • 13.1. Total Market size of SLE in Japan
  • 13.2. Market size of SLE by Current Therapies
  • 13.3. Market size of SLE by Emerging Therapies

14. Market Drivers

15. Market Barriers

16. KOL Views

17. Appendix

  • 17.1. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables

  • Table 1: Major clinical manifestations of Systemic Lupus Erythematosus (SLE)
  • Table 2: Summary of key pathogenic processes, cells, and molecules in SLE
  • Table 3: Differential Diagnosis of Systemic Lupus Erythematosus
  • Table 4: Diagnostic criteria for Systemic Lupus Erythematosus
  • Table 5: Classification criteria for Systemic Lupus Erythematosus
  • Table 6: Total Diagnosed Prevalent cases of SLE in 7MM (2017-2028)
  • Table 7: Total Diagnosed Prevalent Cases of SLE in the US (2017-2028)
  • Table 8: Gender -Specific Prevalent Cases of SLE in the US (2017-2028)
  • Table 9: Severity Specific Prevalent Cases of SLE in the US (2017-2028)
  • Table 10: Total Diagnosed Prevalent Cases of SLE in Germany (2017-2028)
  • Table 11: Gender Specific Prevalent Cases of SLE in Germany (2017-2028)
  • Table 12: Severity Specific Prevalent Cases of SLE in Germany (2017-2028)
  • Table 13: Total Diagnosed Prevalent Cases of SLE in France (2017-2028)
  • Table 14: Gender Specific Prevalent Cases of SLE in France (2017-2028)
  • Table 15: Severity Specific Prevalent Cases of SLE in France (2017-2028)
  • Table 16: Total Diagnosed Prevalent Cases of SLE in Italy (2017-2028)
  • Table 17: Gender Specific Prevalent Cases of SLE in Italy (2017-2028)
  • Table 18: Severity Specific Prevalent Cases of SLE in Italy (2017-2028)
  • Table 19: Total Diagnosed Prevalent Cases of SLE in Spain (2017-2028)
  • Table 20: Gender Specific Prevalent Cases of SLE in Spain (2017-2028)
  • Table 21: Severity Specific Prevalent Cases of SLE in Spain (2017-2028)
  • Table 22: Total Diagnosed Prevalent Cases of SLE in the UK (2017-2028)
  • Table 23: Gender Specific Prevalent Cases of SLE in the UK (2017-2028)
  • Table 24: Severity Specific Prevalent Cases of SLE in the UK (2017-2028)
  • Table 25: Total Diagnosed Prevalent Cases of SLE in Japan (2017-2028)
  • Table 26: Gender Specific Prevalent Cases of SLE in Japan (2017-2028)
  • Table 27: Severity Specific Prevalent Cases of SLE in Japan (2017-2028)
  • Table 28: 2019 EULAR Recommendations for the management of SLE
  • Table 29: Benlysta, Clinical Trial Description, 2019
  • Table 30: Clinical Response Rate in Patients with SLE after 52 weeks of treatment
  • Table 31: Key cross competition- Phase III Drugs
  • Table 32: Key cross competition - Phase II drugs
  • Table 33: Key cross competition- Other Emerging Potential Therapies
  • Table 34: Key cross competition- Other Potential Therapies (Cntd.)
  • Table 35: Anifrolumab, Clinical Trial Description, 2019
  • Table 36: Lupuzor, Clinical Trial Description, 2019
  • Table 37: Baricitinib, Clinical Trial Description, 2019
  • Table 38: Stelara, Clinical Trial Description, 2019
  • Table 39: Atacicept, Clinical Trial Description, 2019
  • Table 40: ILT-101, Clinical Trial Description, 2019
  • Table 41: BIIB059, Clinical Trial Description, 2019
  • Table 42: CC-220, Clinical Trial Description, 2019
  • Table 43: Dapirolizumab pegol, Clinical Trial Description, 2019
  • Table 44: IFNα Kinoid, Clinical Trial Description, 2019
  • Table 45: Cenerimod, Clinical Trial Description, 2019
  • Table 46: KZR-616, Clinical Trial Description, 2019
  • Table 47: BMS-931699, Clinical Trial Description, 2019
  • Table 48: XmAb5871, Clinical Trial Description, 2019
  • Table 49: RSLV-132, Clinical Trial Description, 2019
  • Table 50: VIB7734, Clinical Trial Description, 2019
  • Table 51: Tofacitinib, Clinical Trial Description, 2019
  • Table 52: Total Market Size of SLE in 7MM in USD Million (2017-2028)
  • Table 53: Total Market Size of SLE in 7MM in USD Million (2017-2028)
  • Table 54: Total Market size of SLE in the US (2017-2028)
  • Table 55: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Table 56:Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Table 57: Total Market size of SLE in Germany (2017-2028)
  • Table 58: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Table 59: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Table 60: Market size of SLE in France (2017-2028)
  • Table 61: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Table 62: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Table 63: Total Market size of SLE in Italy (2017-2028)
  • Table 64: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Table 65: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Table 66: Total Market size of Systemic Lupus Erythematosus (SLE) in Spain (2017-2028)
  • Table 67: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Table 68: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Table 69: Total Market size of SLE in the UK (2017-2028)
  • Table 70: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Table 71: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Table 72: Total Market size of SLE in Japan (2017-2028)
  • Table 73: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Table 74:Market Size of SLE by Emerging Therapies in USD Million (2017-2028)

List of Figures

  • Figure 1: Management of Systemic Lupus Erythematosus
  • Figure 2: Risk Factors of SLE
  • Figure 3: T-cell Signaling and Gene regulation in SLE
  • Figure 4: Role of Innate Cells (Neutrophils, Macrophages, and Dendritic Cells) in SLE
  • Figure 5: Algorithm for the diagnosis of Systemic Lupus Erythematosus
  • Figure 6: Total Diagnosed Prevalent cases of SLE in 7MM (2017-2028)
  • Figure 7: Total Diagnosed Prevalent Cases of SLE in the US (2017-2028)
  • Figure 8: Gender -Specific Cases of SLE in the US (2017-2028)
  • Figure 9: Severity Specific Cases of SLE in the US (2017-2028)
  • Figure 10: Total Diagnosed Prevalent Cases of SLE in Germany (2017-2028)
  • Figure 11: Gender -Specific Cases of SLE in Germany (2017-2028)
  • Figure 12: Severity Specific Cases of SLE in Germany (2017-2028)
  • Figure 13: Total Diagnosed Prevalent Cases of SLE in France (2017-2028)
  • Figure 14: Gender Specific Cases of SLE in France (2017-2028)
  • Figure 15: Severity Specific Cases of SLE in France (2017-2028)
  • Figure 16: Total Diagnosed Prevalent Cases of SLE in Italy (2017-2028)
  • Figure 17: Gender Specific Cases of SLE in Italy (2017-2028)
  • Figure 18: Severity Specific Cases of SLE in Italy (2017-2028)
  • Figure 19: Total Diagnosed Prevalent Cases of SLE in Spain (2017-2028)
  • Figure 20: Gender Specific Cases of SLE in Spain (2017-2028)
  • Figure 21: Severity Specific Cases of SLE in Spain (2017-2028)
  • Figure 22: Total Diagnosed Prevalent Cases of SLE in the UK (2017-2028)
  • Figure 23: Gender Specific Cases of SLE in the UK (2017-2028)
  • Figure 24: Severity Specific Cases of SLE in the UK (2017-2028)
  • Figure 25: Total Diagnosed Prevalent Cases of SLE in Japan (2017-2028)
  • Figure 26: Gender Specific Cases of SLE in Japan (2017-2028)
  • Figure 27: Severity Specific Cases of SLE in Japan (2017-2028)
  • Figure 28: Treatment of Non-renal SLE
  • Figure 29: Unmet need: Failure of Numerous clinical trials
  • Figure 30: Unmet Need: Complexity in Pathophysiology of the diseases
  • Figure 31: Steps to fulfill the current unmet need
  • Figure 32: Total Market Size of SLE in 7MM in USD Million (2017-2028)
  • Figure 33: Total Market Size of SLE in 7MM in USD Million (2017-2028)
  • Figure 34: Market size of SLE in the US (2017-2028)
  • Figure 35: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Figure 36: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Figure 37: Total Market size of SLE in Germany (2017-2028)
  • Figure 38: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Figure 39: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Figure 40: Market size of SLE in France (2017-2028)
  • Figure 41: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Figure 42: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Figure 43: Total Market size of SLE in Italy (2017-2028)
  • Figure 44: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Figure 45: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Figure 46: Total Market size of SLE in Spain (2017-2028)
  • Figure 47: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Figure 48: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Figure 49: Total Market size of SLE in the UK (2017-2028)
  • Figure 50: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Figure 51: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Figure 52: Total Market size of SLE in Japan (2017-2028)
  • Figure 53: Market Size of SLE by Current Therapies in USD Million (2017-2028)
  • Figure 54: Market Size of SLE by Emerging Therapies in USD Million (2017-2028)
  • Figure 55: Market Drivers
  • Figure 56:Market Barriers
Back to Top